Why Western pharma is sleeping on China’s circular RNA revolution
The CEO of Therorna discusses the science of behind circular RNA and why Western pharma hasn't paid enough attention to what's being built in China. The post Why Western pharma is sleeping on China’s circular RNA revolution appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s…
Welcome to Beyond Biotech, the official Labiotech.eu podcast. Each week, we delve into the world of biotech, discussing the latest news and interviewing industry experts. Today, we're joined by Dr. Lu Gao, CEO of Therorna Inc., a clinical-stage biotech based in Beijing and Shanghai. Therorna Inc. has developed a proprietary circular RNA (circRNA) platform, which has garnered attention for its potential advantages over linear mRNA.
Despite its promising potential, Western pharma companies have seemingly overlooked this Chinese innovation. In this interview, we'll explore the science behind circRNA, Therorna's clinical strategy, and the reasons behind the lack of Western pharmaceutical interest in this cutting-edge technology.
Written by urgent.news from Labiotech's reporting — not their text. Machine-written; read the original for the full account.
